Join us for an audio catch-up on the major events in the global biopharma industry over the past business week, as reported by Scrip‘s global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 30 May 2025, including: a preview of major ASCO readouts; Roivant stays patient in deals; Lilly diversifies pain pipeline with SiteOne acquisition; Nucala gets US COPD nod; and women in Indian pharma.
This and all our other podcasts are available on the Citeline channel on Apple Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories Mentioned In This Episode:
- ASCO Preview: Major Solid Tumor Readouts Include AstraZeneca/Daiichi, Gilead ADCs
- Roivant Staying ‘Patient’ On Deals, Leaving Investors Waiting
- Lilly To Diversify Pain Pipeline With SiteOne Acquisition
- GSK’s Nucala Set For Dupixent Face-Off After FDA COPD Nod
- Pharma Women’s Workforce In India: Weak Start, Promotions, C-Suite Drop Off
